This article covers the FDA shortage-list context that opened the compounding pathway, the 2024 shortage resolution that narrowed it, the difference between legitimate 503A compounding pharmacies and unregulated sources, and how PlexusDx operates inside the legitimate pathway
Precursors such as NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are raw materials the body can convert toward NAD+ over time
The 18.4% OOS rate is the second-highest in the deep-dive group
Are the impurities identified
If you or a loved one has been diagnosed with any of the following conditions after taking Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Rybelsus, or Victoza, you may be eligible to file a legal claim against the drug manufacturers, Novo Nordisk and Eli Lilly: Gastroparesis Intestinal blockage Bowel obstruction Ileus Intestinal pseudo-blockage As the landscape of GLP-1 agonist litigation evolves, including potential future claims related to NAION, Cory Watson Attorneys remains committed to advocating for patient safety and holding pharmaceutical companies accountable for the harm their products may cause
